Physician profile
Diana Lynn Hunter
NPI 1518903376
$5,453.30
in general payments reported to CMS, 2019-2025
29 companies · $2,126 in 2025
The $2,126 reported for 2025 was more than what 92% of Adult Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $186).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $550 · 2022: $705 · 2023: $775 · 2024: $1,297 · 2025: $2,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,993 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,992.65 |
| Education | $205.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,693.76 | 2021-2025 | |
| Janssen Biotech, INC. | $695.84 | 2024-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $593.36 | 2021-2024 | Ocaliva |
| Evoke Pharma, INC. | $313.59 | 2022-2024 | Gimoti |
| Phathom Pharmaceuticals, INC. | $312.04 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $236.59 | 2021-2024 | Airsupra |
| Gilead Sciences, INC. | $229.86 | 2024-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $177.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $161.14 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $156.11 | 2024-2025 | Vowst |
| Regeneron Healthcare Solutions, INC. | $118.99 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $105.28 | 2025 | Iqirvo |
| Lilly USA, LLC | $102.89 | 2025 | Omvoh |
| Alexion Pharmaceuticals, INC. | $94.97 | 2023 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.92 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $57.14 | 2021-2022 | |
| Novo Nordisk INC | $51.51 | 2022-2025 | Wegovy |
| Vivus LLC | $42.68 | 2025 | Qsymia |
| Takeda Pharmaceuticals U.S.A., INC. | $40.24 | 2025 | Eohilia |
| Janssen Pharmaceuticals, INC | $38.58 | 2021 | |
| Qol Medical, LLC | $28.91 | 2025 | Sucraid |
| Ardelyx, INC. | $20.25 | 2025 | Ibsrela |
| Biogen, INC. | $19.39 | 2022 | |
| Celltrion USA INC. | $16.90 | 2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Stryker Corporation | $13.26 | 2024 | Neptune |
| Merck Sharp & Dohme LLC | $12.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.96 | 2022 | |
| Glaxosmithkline, LLC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.